WO2003035894A3 - Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample - Google Patents

Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample Download PDF

Info

Publication number
WO2003035894A3
WO2003035894A3 PCT/US2002/034397 US0234397W WO03035894A3 WO 2003035894 A3 WO2003035894 A3 WO 2003035894A3 US 0234397 W US0234397 W US 0234397W WO 03035894 A3 WO03035894 A3 WO 03035894A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
rare
detection
assay
blood
Prior art date
Application number
PCT/US2002/034397
Other languages
French (fr)
Other versions
WO2003035894A2 (en
WO2003035894A8 (en
Inventor
Shawn Mark O'hara
Daniel Zweitzig
Brad Foulk
Original Assignee
Immunivest Corp
Shawn Mark O'hara
Daniel Zweitzig
Brad Foulk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunivest Corp, Shawn Mark O'hara, Daniel Zweitzig, Brad Foulk filed Critical Immunivest Corp
Priority to CA002465274A priority Critical patent/CA2465274A1/en
Priority to AU2002360305A priority patent/AU2002360305A1/en
Priority to EP02795554A priority patent/EP1438398A2/en
Publication of WO2003035894A2 publication Critical patent/WO2003035894A2/en
Publication of WO2003035894A3 publication Critical patent/WO2003035894A3/en
Publication of WO2003035894A8 publication Critical patent/WO2003035894A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A highly sensitive assay is disclosed which utilizes a method for gene specific primed amplification of mRNA libraries from rare cells and rare transcripts found in blood. The assay allows detection of rare mRNA (10 copies/cell) found in 1 to 10 cells isolated through immunomagnetic enrichment. The assay is an improvement over multiplex PCR and allows efficient detection of rare coding sequences for circulating carcinoma cells in the blood. The methods are useful in profiling of cells isolated from tissues or body fluids and serves as an adjunct to clinical diagnosis of diverse carcinomas including early stage detection and classification of circulating tumor cells. Monitoring of nucleic acid and protein profiles of cells either in conventional or microarray formats, facilitates management of therapeutic intervention including staging, monitoring response to therapy, confirmation of remission and detection of regression.
PCT/US2002/034397 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample WO2003035894A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002465274A CA2465274A1 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
AU2002360305A AU2002360305A1 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
EP02795554A EP1438398A2 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33066901P 2001-10-26 2001-10-26
US60/330,669 2001-10-26
US36994502P 2002-04-04 2002-04-04
US60/369,945 2002-04-04

Publications (3)

Publication Number Publication Date
WO2003035894A2 WO2003035894A2 (en) 2003-05-01
WO2003035894A3 true WO2003035894A3 (en) 2003-12-04
WO2003035894A8 WO2003035894A8 (en) 2004-06-03

Family

ID=26987390

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/034397 WO2003035894A2 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
PCT/US2002/034570 WO2003035895A2 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034570 WO2003035895A2 (en) 2001-10-26 2002-10-28 Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample

Country Status (9)

Country Link
EP (2) EP1438398A2 (en)
JP (1) JP2005507997A (en)
KR (1) KR20040047971A (en)
CN (1) CN1610752A (en)
AU (1) AU2002360305A1 (en)
BR (1) BR0213520A (en)
CA (2) CA2465274A1 (en)
IL (1) IL161357A0 (en)
WO (2) WO2003035894A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
AU2003216175A1 (en) 2002-02-04 2003-09-02 Colorado School Of Mines Laminar flow-based separations of colloidal and cellular particles
WO2004029221A2 (en) 2002-09-27 2004-04-08 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
EP1678327A4 (en) * 2003-10-16 2007-10-10 Genomic Health Inc Qrt-pcr assay system for gene expression profiling
US7332597B2 (en) 2004-06-28 2008-02-19 University Of Kentucky Research Foundation Primers and probe to identify mycobacterium tuberculosis complex
ITBO20040420A1 (en) 2004-07-07 2004-10-07 Type S R L METAL CUTTING AND FORMING MACHINE
DE102005013261A1 (en) * 2005-03-22 2006-09-28 Adnagen Ag Reagent and method for preventing time-dependent expression in biological cells
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
DE102005029808A1 (en) * 2005-06-27 2007-01-04 Siemens Ag Support material, process for its preparation and use
ITBO20050481A1 (en) 2005-07-19 2007-01-20 Silicon Biosystems S R L METHOD AND APPARATUS FOR THE HANDLING AND / OR IDENTIFICATION OF PARTICLES
KR101446626B1 (en) 2005-09-02 2014-10-06 도레이 카부시키가이샤 Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
US20070059683A1 (en) * 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
CA2623405C (en) 2005-09-20 2014-11-25 Immunivest Corporation Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
ITBO20050646A1 (en) 2005-10-26 2007-04-27 Silicon Biosystem S R L METHOD AND APPARATUS FOR CHARACTERIZATION AND COUNTING OF PARTICLES
US9878326B2 (en) 2007-09-26 2018-01-30 Colorado School Of Mines Fiber-focused diode-bar optical trapping for microfluidic manipulation
US9487812B2 (en) 2012-02-17 2016-11-08 Colorado School Of Mines Optical alignment deformation spectroscopy
US9885644B2 (en) 2006-01-10 2018-02-06 Colorado School Of Mines Dynamic viscoelasticity as a rapid single-cell biomarker
US8119976B2 (en) 2007-07-03 2012-02-21 Colorado School Of Mines Optical-based cell deformability
ITTO20060226A1 (en) 2006-03-27 2007-09-28 Silicon Biosystem S P A METHOD AND APPARATUS FOR PROCESSING AND OR ANALYSIS AND OR SELECTION OF PARTICLES, IN PARTICULAR BIOLOGICAL PARTICLES
WO2007121465A2 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc Use of highly parallel snp genotyping for fetal diagnosis
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp Methods and compositions for detecting rare cells from a biological sample
JP4926812B2 (en) * 2007-02-01 2012-05-09 シスメックス株式会社 Blood cell analyzer and body fluid analysis method
US10722250B2 (en) 2007-09-04 2020-07-28 Colorado School Of Mines Magnetic-field driven colloidal microbots, methods for forming and using the same
ITTO20070771A1 (en) 2007-10-29 2009-04-30 Silicon Biosystems Spa METHOD AND APPARATUS FOR IDENTIFICATION AND HANDLING OF PARTICLES
IT1391619B1 (en) * 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
SG174459A1 (en) 2009-03-17 2011-10-28 Silicon Biosystems Spa Microfluidic device for isolation of cells
JP5729904B2 (en) * 2009-06-02 2015-06-03 キヤノン株式会社 Methods for preparing proteins, DNA, RNA from cells
EP2479268B1 (en) * 2009-09-17 2020-11-04 JSR Corporation Dissociation method and dissociation agent for avidin and biotinderivatives
JP5876834B2 (en) * 2010-01-04 2016-03-02 キアジェン ゲイサーズバーグ インコーポレイテッド Methods, compositions, and kits for the recovery of nucleic acids or proteins from fixed tissue samples
WO2012034013A2 (en) 2010-09-10 2012-03-15 Bio-Rad Laboratories, Inc. Detection of rna-interacting regions in dna
CN102565404B (en) * 2010-12-24 2014-04-16 牛刚 Kit for detecting free colorectal cancer cell markers in blood
CN102156164B (en) * 2011-01-13 2012-12-12 北京肿瘤医院 Mass spectra identification method of nucleophosmin variable spliceosome and gastric cancer diagnostic reagent kit
CN102109525B (en) * 2011-01-26 2013-10-16 牛刚 Kit for detecting free breast cancer cell marker in blood
WO2012112606A1 (en) 2011-02-15 2012-08-23 Bio-Rad Laboratories, Inc. Detecting methylati0n in a subpopulation of genomic dna
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
EP2739752B1 (en) * 2011-08-03 2017-07-19 Bio-Rad Laboratories, Inc. Filtering small nucleic acids using permeabilized cells
ITTO20110990A1 (en) 2011-10-28 2013-04-29 Silicon Biosystems Spa METHOD AND APPARATUS FOR OPTICAL ANALYSIS OF LOW TEMPERATURE PARTICLES
ITBO20110766A1 (en) 2011-12-28 2013-06-29 Silicon Biosystems Spa DEVICES, EQUIPMENT, KITS AND METHOD FOR THE TREATMENT OF A BIOLOGICAL SAMPLE
WO2014067528A1 (en) * 2012-10-29 2014-05-08 Arcedi Biotech Aps Improved enrichment and detection of rare blood cells
CN105102960B (en) * 2013-03-15 2017-12-29 艾瑞思国际股份有限公司 For the method and composition for being dyed and being handled to urine sample
US9857361B2 (en) 2013-03-15 2018-01-02 Iris International, Inc. Flowcell, sheath fluid, and autofocus systems and methods for particle analysis in urine samples
US9771571B2 (en) 2014-02-28 2017-09-26 Gen-Probe Incorporated Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde
EP3670664B1 (en) * 2014-02-28 2022-09-07 Gen-Probe Incorporated Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde
US9771572B2 (en) 2014-02-28 2017-09-26 Gen-Probe Incorporated Method of isolating nucleic acid from specimens in liquid-based cytology preservatives containing formaldehyde
JP2014158468A (en) * 2014-03-05 2014-09-04 Clinical Genomics Pty Ltd Detection method
AU2016219328B2 (en) * 2015-02-10 2022-04-21 Illumina, Inc. Methods and compositions for analyzing cellular components
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10282588B2 (en) * 2016-06-09 2019-05-07 Siemens Healthcare Gmbh Image-based tumor phenotyping with machine learning from synthetic data
CN110456034B (en) * 2018-05-07 2022-07-22 上海市第十人民医院 Detection method of circulating tumor cells
CN109402240B (en) * 2019-01-08 2020-08-25 圣湘生物科技股份有限公司 Nucleic acid releasing agent, nucleic acid PCR amplification method and PCR amplification kit
WO2023080601A1 (en) * 2021-11-05 2023-05-11 고려대학교 세종산학협력단 Disease diagnosis method and device using machine learning-based lens-free shadow imaging technology

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929556A (en) * 1986-02-06 1990-05-29 The Dow Chemical Company Enzyme immobilization with polysulfonium salts
US5346994A (en) * 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
US6156564A (en) * 1996-06-07 2000-12-05 The United States Of America As Represented By The Department Of Health And Human Services Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
US6365362B1 (en) * 1998-02-12 2002-04-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6156515A (en) * 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929556A (en) * 1986-02-06 1990-05-29 The Dow Chemical Company Enzyme immobilization with polysulfonium salts
US5346994A (en) * 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6156564A (en) * 1996-06-07 2000-12-05 The United States Of America As Represented By The Department Of Health And Human Services Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US6365362B1 (en) * 1998-02-12 2002-04-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
KR20040047971A (en) 2004-06-05
WO2003035895A3 (en) 2004-01-08
EP1438398A2 (en) 2004-07-21
CA2465274A1 (en) 2003-05-01
IL161357A0 (en) 2004-09-27
AU2002360305A1 (en) 2003-05-06
CN1610752A (en) 2005-04-27
JP2005507997A (en) 2005-03-24
EP1438419A2 (en) 2004-07-21
WO2003035894A2 (en) 2003-05-01
WO2003035894A8 (en) 2004-06-03
BR0213520A (en) 2006-05-23
WO2003035895A2 (en) 2003-05-01
CA2465288A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2003035894A8 (en) Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
Goidin et al. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations
Keilholz et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group
US20190249260A1 (en) Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
AU767983B2 (en) Methods for detecting nucleic acids indicative of cancer
WO2005098046A3 (en) Methods for the determination of cell specific biomarkers
CA2455731A1 (en) Methods for evaluating pathologic conditions using extracellular rna
CA2435917A1 (en) Highly sensitive method for the detection of cytosine methylation patterns
EP2816121A2 (en) Method for obtaining information on hepatocellular carcinoma and marker and kit for obtaining information on hepatocellular carcinoma
EP2357255A2 (en) Assay for methylation in the GST-Pi gene
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
WO2002079411A3 (en) Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
Takano et al. Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy
US20100233722A1 (en) Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA
CN107475388B (en) Application of nasopharyngeal carcinoma related miRNA as biomarker and nasopharyngeal carcinoma detection kit
NO20032697L (en) Test strip assay system and assay method for detection and / or determination of specific nucleic acid sequences
CA2462932A1 (en) Method for the detection of cytosine methylations in immobilized dna samples
JP2023109998A (en) Detection of microsatellite instability
EP2808397A2 (en) Method for obtaining information on colon cancer and marker and kit for obtaining information on colon cancer
CN100371459C (en) Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA
US20080286784A1 (en) Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
CN116219020B (en) Methylation reference gene and application thereof
Krstulovic et al. High performance liquid chromatographic determination of serum UV profiles of normal subjects and patients with breast cancer and benign fibrocystic changes
CN113999901B (en) Myocardial specific methylation markers
Jin et al. Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002795554

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003538394

Country of ref document: JP

Ref document number: 2465274

Country of ref document: CA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 18/2003 UNDER (72, 75) REPLACE "[-/US]" BY "[US/US]"; ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

WWP Wipo information: published in national office

Ref document number: 2002795554

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002795554

Country of ref document: EP